<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00611507</url>
  </required_header>
  <id_info>
    <org_study_id>L_8107</org_study_id>
    <nct_id>NCT00611507</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer</brief_title>
  <official_title>A Phase II Study of Oxaliplatin in Association With 5FU and Folinic Acid in the Treatment of Subjects With Non-Surgical or Advanced Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      This phase II trial will evaluate, in first line advanced or metastatic gastric cancer, the&#xD;
      efficacy and tolerance of another oxaliplatin, 5FU bolus combination already tested in&#xD;
      advanced colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">April 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate - RECIST criteria (unidimensional)</measure>
    <time_frame>During the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Stomach Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin, 5-Fluorouracil</intervention_name>
    <description>5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.</description>
    <other_name>Eloxatin, 5FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven gastric or gastroesophagic junction adenocarcinoma&#xD;
&#xD;
          -  Measurable disease at least in a unidimensional manner. If a unique metastasis&#xD;
             constitutes the only disease symptom, histological confirmation will be required&#xD;
&#xD;
          -  Metastatic or locally non-surgical primary gastric cancer&#xD;
&#xD;
          -  Recurrent gastric cancer after local and/or systemic treatment with a post-surgical&#xD;
             period of at least 4 weeks, a post-adjuvant chemotherapy period or a neo-adjuvant&#xD;
             chemo-radiotherapy of at least 6 months&#xD;
&#xD;
          -  Serum bilirubin&lt; 2 mg/dl&#xD;
&#xD;
          -  Serum creatinine &lt; or =to 2 times normal superior limit&#xD;
&#xD;
          -  Absolute neutrophil count &gt; or =to 2000/dl&#xD;
&#xD;
          -  Platelet count &gt; or =to 100000/dl&#xD;
&#xD;
          -  Hemoglobin &gt; or =to 10 g/dl&#xD;
&#xD;
          -  AST/ALT &lt; or =to 2.5 times normal superior institutional limit&#xD;
&#xD;
          -  Alkaline phosphatase &lt; or =to 5 times the normal superior institutional limit&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Performance Status ECOG 0-2&#xD;
&#xD;
          -  Written informed consent signed and dated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic sensory peripheral neuropathy&#xD;
&#xD;
          -  Uncontrolled concomitant disease.(e.g. severe diabetes mellitus, arterial&#xD;
             hypertension)&#xD;
&#xD;
          -  Any other malignancy diagnosed within 5 years previous to the gastric cancer, with the&#xD;
             exception of &quot; in situ &quot; cervix carcinoma or non-melanoma skin cancer&#xD;
&#xD;
          -  Concomitant anti-tumoral treatment&#xD;
&#xD;
          -  Cerebral metastases&#xD;
&#xD;
          -  Unstable heart disease, even though under treatment&#xD;
&#xD;
          -  Myocardial infarction within the last 6 months&#xD;
&#xD;
          -  Pregnancy or nursing (or women in reproductive life without adequate contraception)&#xD;
&#xD;
          -  Significant neurological or psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos Gomez</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>January 28, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2008</study_first_posted>
  <last_update_submitted>March 24, 2008</last_update_submitted>
  <last_update_submitted_qc>March 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Juan Carlos Gomez/Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

